Show simple item record

dc.contributor.authorGodman, Brian
dc.contributor.authorFinlayson, Alexander E
dc.contributor.authorCheema, Parneet K
dc.contributor.authorZebedin-Brandl, Eva
dc.contributor.authorGutiérrez-Ibarluzea, Inaki
dc.contributor.authorJones, Jan
dc.contributor.authorMalmström, Rickard E
dc.contributor.authorAsola, Elina
dc.contributor.authorBaumgärtel, Christoph
dc.contributor.authorBennie, Marion
dc.contributor.authorBishop, Iain
dc.contributor.authorBucsics, Anna
dc.contributor.authorCampbell, Stephen
dc.contributor.authorDiogene, Eduardo
dc.contributor.authorFerrario, Alessandra
dc.contributor.authorFürst, Jurij
dc.contributor.authorGaruoliene, Kristina
dc.contributor.authorGomes, Miguel
dc.contributor.authorHarris, Katharine
dc.contributor.authorHaycox, Alan
dc.contributor.authorHerholz, Harald
dc.contributor.authorHviding, Krystyna
dc.contributor.authorJan, Saira
dc.contributor.authorKalaba, Marija
dc.contributor.authorKvalheim, Christina
dc.contributor.authorLaius, Ott
dc.contributor.authorLööv, Sven-Ake
dc.contributor.authorMalinowska, Kamila
dc.contributor.authorMartin, Andrew
dc.contributor.authorMcCullagh, Laura
dc.contributor.authorNilsson, Fredrik
dc.contributor.authorPaterson, Ken
dc.contributor.authorSchwabe, Ulrich
dc.contributor.authorSelke, Gisbert
dc.contributor.authorSermet, Catherine
dc.contributor.authorSimoens, Steven
dc.contributor.authorTomek, Dominik
dc.contributor.authorVlahovic-Palcevski, Vera
dc.contributor.authorVoncina, Luka
dc.contributor.authorWladysiuk, Magdalena
dc.contributor.authorvan Woerkom, Menno
dc.contributor.authorWong-Rieger, Durhane
dc.contributor.authorZara, Corrine
dc.contributor.authorAli, Raghib
dc.contributor.authorGustafsson, Lars L
dc.date.accessioned2013-11-13T10:31:53Z
dc.date.available2013-11-13T10:31:53Z
dc.date.issued2013-08-13
dc.identifier.citationBMC Medicine. 2013 Aug 13;11(1):179en_GB
dc.identifier.urihttp://dx.doi.org/10.1186/1741-7015-11-179
dc.identifier.urihttp://hdl.handle.net/10147/305321
dc.description.abstractAbstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.
dc.language.isoenen
dc.subjectHEALTH CAREen_GB
dc.subjectPATIENT SATISFACTIONen_GB
dc.subjectQUALITY IMPROVEMENTen_GB
dc.titlePersonalizing health care: feasibility and future implicationsen_GB
dc.identifier.journalBMC medicineen_GB
dc.language.rfc3066en
dc.rights.holderBrian Godman et al.; licensee BioMed Central Ltd.
dc.description.statusPeer Reviewed
dc.date.updated2013-11-13T05:09:20Z
refterms.dateFOA2018-08-23T09:43:07Z
html.description.abstractAbstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.


Files in this item

Thumbnail
Name:
1741-7015-11-179.xml
Size:
279.6Kb
Format:
XML
Thumbnail
Name:
1741-7015-11-179.pdf
Size:
1.200Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record